Pediatrics

Pneumococcal Vaccine Becomes Available

Published in Medical Letter on the CDC and FDA, April 25th, 2000

The U.S. Food and Drug Administration's recent approval of a new vaccine developed specifically for infants and toddlers is expected to have a significant impact in the number of cases of pneumococcal infections - illnesses that can have devastating effects, according to Deborah Lehman, MD, a specialist in pediatric infectious diseases.

Prevnar, the vaccine produced by American Home Products Corp., is intended to prevent pneumococcal bacteremia - infection of the bloodstream - and pneumococcal meningitis - infection of the lining of the brain and spinal cord.

"Pneumococcal meningitis is the worst-case scenario, with a fairly high mortality rate and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-04-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry